Status:

RECRUITING

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Haystack Oncology, Inc.

Conditions:

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Eligibility:

All Genders

18+ years

Brief Summary

This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinoma...

Detailed Description

PRIMARY OBJECTIVE: I. To determine the rates of detectable ctDNA within two years of participants treated with curative-intent surgery or radiation-based treatment for HNC. SECONDARY OBJECTIVES: 1....

Eligibility Criteria

Inclusion

  • Participants must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck mucosa and skin.
  • Participants must be age \>=18 years.
  • Participants must be planning to receive curative-intent surgery or radiation-based treatment as part of standard of care treatment.
  • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion

  • 1\. Contraindication to phlebotomy for removal of 20 mL of peripheral blood each time point (up to 300 mL total over 15 time points).

Key Trial Info

Start Date :

October 9 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2029

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT06606028

Start Date

October 9 2024

End Date

December 30 2029

Last Update

December 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94143

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma | DecenTrialz